Natco Pharma Q1FY27: Revenue ₹7,944 Cr, PAT ₹2,065 Cr, EPS ₹11.53
Natco Pharma reported Q1FY27 revenue of ₹7,944 crore and PAT of ₹2,065 crore. EPS stood at ₹11.53. International Formulations contributed ₹4,771 crore, and Domestic Formulations ₹1,364 crore. The company received U.S. FDA approval for Eribulin Mesylate Injection. An earnings call is scheduled for August 14, 2026.
The announcement includes key financial highlights for the quarter, U.S. FDA approval for a product, and details on the company's pipeline and investments, which are material information for investors.
The company reported strong financial results with significant revenue and profit growth, alongside receiving U.S. FDA approval for a key product, indicating positive business performance and outlook.
Natco Pharma Limited announced its financial results for the first quarter of the fiscal year 2027 (Q1FY27), ending June 30, 2026. The company reported a consolidated total revenue of ₹7,944 crore (INR 7,944 Mn), with International Formulations contributing ₹4,771 crore (INR 4,771 Mn) and Domestic Formulations generating ₹1,364 crore (INR 1,364 Mn).
Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) stood at ₹2,457 crore (INR 2,457 Mn), with an EBITDA margin of 30.9%. The profit after tax (PAT) for the quarter was ₹2,065 crore (INR 2,065 Mn), resulting in a profit margin of 26%. The reported Earnings Per Share (EPS) for Q1FY27 was ₹11.53 per share.
The company also provided an update on its associate, Adcock Ingram Holdings Ltd, with a profit share of ₹843 crore (INR 843 Mn) for Q1FY27. Natco Pharma received final approval for Eribulin Mesylate Injection from the U.S. FDA. The company is also advancing its product pipeline, including key Para IV products and Sole FTFs in the USA, and has made significant investments in NCE and Cell & Gene Therapy, including eGenesis, Cellogen Therapeutics, and Stero Therapeutics.
Natco Pharma is scheduled to hold an earnings call on August 14, 2026, at 5:30 PM IST to discuss its operational and financial performance. Key management personnel, including Mr. Rajeev Nannapaneni (Vice Chairman and CEO) and Mr. Amit Parekh (CFO), will be participating in the call.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.